Filana Therapeutics — Q3 2026 Earnings Summary

Filana Therapeutics reported a net loss of $10.7 million for the third quarter of 2026, with cash and cash equivalents totaling $47.0 million as of September 30. The company's investigational drug simufilam received FDA approval to lift a clinical hold in September 2026, enabling preparations for a Phase 2a study in TSC-related epilepsy expected to begin patient screening in the first quarter of 2027. During the quarter, research and development expenses decreased to $3.9 million while general and administrative expenses fell to $7.4 million. Additionally, the company transferred $31.25 million into escrow in July 2026 to settle potential securities litigation, which is recorded as restricted cash.